The GLP-1 market is dominated by Eli Lilly and Novo Nordisk, but Pfizer is making significant efforts to enter this competitive field, despite facing some challenges. The company recently announced a $5 billion investment aimed at advancing its position in the market, prompting an evaluation of Pfizer’s potential for investors.
